The geniuses of biotech—the Mozarts and Beethovens, as Generate Biomedicines CEO Mike Nally calls them—can only find so many new drugs. Without the limits of human discovery, AI can churn out as many programs as you have servers to run it. But then you hit another limit: how many programs can your biotech actually handle?With […]
